Opus Genetics earnings were -$57.5M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest IRD earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$35.1M, up 366.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, IRD reported annual earnings of -$57.5M, with 476.1% growth.
Opus Genetics (NASDAQ: IRD) reported Q4 2024 earnings per share (EPS) of -$1.27, up 504.76% year over year. Total IRD earnings for the quarter were -$35.14 million. In the same quarter last year, Opus Genetics's earnings per share (EPS) was -$0.21.
As of the last Opus Genetics earnings report, Opus Genetics is currently losing money. Opus Genetics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$57.53 million, a 476.13% increase year over year.
What was IRD's earnings growth in the past year?
As of Opus Genetics's earnings date in Q2 2025, Opus Genetics's earnings has grown year over year. IRD earnings in the past year totalled -$57.53 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.